KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bausch Health Companies (BHC) EBIT (2016 - 2025)

Bausch Health Companies' EBIT history spans 17 years, with the latest figure at $474.0 million for Q4 2025.

  • For Q4 2025, EBIT fell 15.05% year-over-year to $474.0 million; the TTM value through Dec 2025 reached $1.8 billion, up 17.27%, while the annual FY2025 figure was $1.8 billion, 17.27% up from the prior year.
  • EBIT for Q4 2025 was $474.0 million at Bausch Health Companies, down from $619.0 million in the prior quarter.
  • Across five years, EBIT topped out at $619.0 million in Q3 2025 and bottomed at -$270.0 million in Q2 2021.
  • The 5-year median for EBIT is $301.5 million (2022), against an average of $261.3 million.
  • The largest YoY upside for EBIT was 7440.0% in 2021 against a maximum downside of 900.0% in 2021.
  • A 5-year view of EBIT shows it stood at $367.0 million in 2021, then tumbled by 164.31% to -$236.0 million in 2022, then soared by 253.39% to $362.0 million in 2023, then soared by 54.14% to $558.0 million in 2024, then decreased by 15.05% to $474.0 million in 2025.
  • Per Business Quant, the three most recent readings for BHC's EBIT are $474.0 million (Q4 2025), $619.0 million (Q3 2025), and $444.0 million (Q2 2025).